Seminars in Oncology
Volume 33, Issue 1 , Pages 74-85, February 2006

Myelotoxicity From Chemotherapy

  • Davey Daniel

      Affiliations

    • Department of Hematology-Medical Oncology, Duke University Medical Center, Durham, NC
    • ,
  • Jeffrey Crawford

      Affiliations

    • Department of of Medical Oncology, Duke University Medical Center, Durham, NC
    • Corresponding Author InformationAddress correspondence to Jeffrey Crawford, MD, Duke University Medical Center, Box 3198 Morris Building, Room 25178, Durham, NC 27710

Myelosuppression continues to be a major dose-limiting toxicity for most chemotherapy regimens. While the development of growth factors has changed the approach to myelosuppression, costs remain high and can be measured both in terms of quality of life (QOL) and economic outcomes. Growing data suggest that there may also be effects on response and survival in some tumors. This review will highlight the incidence, effect, and treatment/prevention of myelosuppression and briefly discuss the questions that remain.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(05)00433-1

doi:10.1053/j.seminoncol.2005.11.003

Seminars in Oncology
Volume 33, Issue 1 , Pages 74-85, February 2006

Article Tools

* Image Usage & Resolution